Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    (A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

    Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.

  • SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

    Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

  • Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

    Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

  • UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

    Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

  • Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NWLjfFkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TGbWlEPTB;MD6wNFA{ODNizszN NYfjUIdZW0GQR1XS
IST-MEL1 NWnHcnVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHmSG1VUUN3ME2wMlAxODRyNzFOwG0> MojDV2FPT0WU
NCI-SNU-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTab4IyUUN3ME2wMlAxOjB5IN88US=> NEfWPVZUSU6JRWK=
FADU NXfsV4k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMECyNFkh|ryP NVnDe2ZLW0GQR1XS
C32 NIjYd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMECzNFQh|ryP NGHwenpUSU6JRWK=
D-566MG NF7GT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMECzPUDPxE1? MVLTRW5ITVJ?
LXF-289 M4\qNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3qeJZKSzVyPUCuNFA1OTlizszN M3rONXNCVkeHUh?=
HGC-27 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEC1NUDPxE1? M3;u[3NCVkeHUh?=
RPMI-7951 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEC3NVch|ryP MUjTRW5ITVJ?
HSC-3 NITyRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz5TWM2OD1yLkCwPVI6KM7:TR?= NEXLS2JUSU6JRWK=
MIA-PaCa-2 NGLG[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEGwNFkh|ryP M1vKfHNCVkeHUh?=
KS-1 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRTWM2OD1yLkCxN|U2KM7:TR?= MX3TRW5ITVJ?
CAL-51 NISwbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;NTWM2OD1yLkCxOFA2KM7:TR?= M1fRfnNCVkeHUh?=
MDA-MB-361 NX3SN|NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M335SGlEPTB;MD6wNVQ6PSEQvF2= MVrTRW5ITVJ?
TI-73 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrUVZJXUUN3ME2wMlAyPzl4IN88US=> MnPKV2FPT0WU
AGS MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XuZmlEPTB;MD6wNVk{QCEQvF2= NYXkOHVFW0GQR1XS
NCI-H460 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojITWM2OD1yLkCxPVc1KM7:TR?= NIjBflJUSU6JRWK=
A204 M1Hyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULZcnpLUUN3ME2wMlAzOjR7IN88US=> NFv6PFNUSU6JRWK=
CHL-1 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rPemlEPTB;MD6wNlI2OSEQvF2= MkDGV2FPT0WU
DU-4475 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\6TWM2OD1yLkCyNlYyKM7:TR?= M4rmSnNCVkeHUh?=
CGTH-W-1 NFyxXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XlW2lEPTB;MD6wNlM1QSEQvF2= NX;JOGpmW0GQR1XS
HCC2218 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjnTWM2OD1yLkCyOFk1KM7:TR?= MUjTRW5ITVJ?
A2780 M3L3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Pm[GlEPTB;MD6wNlU{OSEQvF2= NWTVfm1xW0GQR1XS
NCI-H720 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f6XmlEPTB;MD6wNlU1PiEQvF2= MkPwV2FPT0WU
NCI-N87 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XRN2lEPTB;MD6wNlU6OyEQvF2= MnuwV2FPT0WU
CHP-212 M{nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEK2Nlgh|ryP MXvTRW5ITVJ?
NCI-H23 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMEK2OlUh|ryP MkfyV2FPT0WU
D-263MG NWLMOnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HkNmlEPTB;MD6wNlc5PiEQvF2= NFyyOJZUSU6JRWK=
ME-180 NUHqVIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m1W2lEPTB;MD6wNlg6OSEQvF2= M2jvbHNCVkeHUh?=
SW982 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrrb5BKSzVyPUCuNFI6QTlizszN NUnxXVZ7W0GQR1XS
OE19 NXriUZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOyTWM2OD1yLkCzNFc4KM7:TR?= NGqyWJhUSU6JRWK=
SK-LU-1 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\4VmlEPTB;MD6wN|A5OiEQvF2= M{\RcnNCVkeHUh?=
H4 NUDsXGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33YNGlEPTB;MD6wN|A6KM7:TR?= MVvTRW5ITVJ?
HT-144 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrtTWM2OD1yLkCzNFk{KM7:TR?= NUnqXYhsW0GQR1XS
SK-UT-1 NFfHWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOxSI9QUUN3ME2wMlA{OTd6IN88US=> NVHqZ3FjW0GQR1XS
D-336MG MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEOzNFkh|ryP MWXTRW5ITVJ?
MDA-MB-175-VII M4LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3mdGFKSzVyPUCuNFM{PTRizszN MoTXV2FPT0WU
GAMG NVHCZ2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fQZ2lEPTB;MD6wN|Q{PSEQvF2= NXzaTpJxW0GQR1XS
CP50-MEL-B NYnmdlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjZTWM2OD1yLkCzOFUh|ryP MWPTRW5ITVJ?
OVCAR-5 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEO0PEDPxE1? MWTTRW5ITVJ?
SK-MES-1 NYHoRpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEO2NFYh|ryP NYHxcHhSW0GQR1XS
VM-CUB-1 M1X3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HXOWlEPTB;MD6wN|Y2PyEQvF2= M1;tN3NCVkeHUh?=
WM-115 NH3wOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7LNYlKSzVyPUCuNFM4PjJizszN NYW4UWZGW0GQR1XS
DSH1 M4nJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEO4NFch|ryP MV;TRW5ITVJ?
Becker M3q3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PLdWlEPTB;MD6wN|g5PSEQvF2= M1HIV3NCVkeHUh?=
SW962 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvz[G1KSzVyPUCuNFM6PDVizszN NIjybnVUSU6JRWK=
TYK-nu NGnHfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjPTWM2OD1yLkCzPVg2KM7:TR?= M4K1ZnNCVkeHUh?=
HO-1-N-1 NHH4dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3jbplKSzVyPUCuNFQxOjFizszN M{jZ[HNCVkeHUh?=
T98G NUfhOnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLwVHhKSzVyPUCuNFQyODNizszN Mn;MV2FPT0WU
ACN NV7lOnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L4dWlEPTB;MD6wOFE3OiEQvF2= NWWw[2M5W0GQR1XS
SW780 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMESyNFMh|ryP M1fuOnNCVkeHUh?=
Detroit562 M1K4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrrTWM2OD1yLkC0NlM6KM7:TR?= M{L3VHNCVkeHUh?=
BB49-HNC M1fpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMESyOFMh|ryP M{CwOHNCVkeHUh?=
HN M3LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPDV4pxUUN3ME2wMlA1Ojd{IN88US=> MkT2V2FPT0WU
H9 M1HYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLqTWM2OD1yLkC0N|cyKM7:TR?= M3ewNnNCVkeHUh?=
VA-ES-BJ NYe3fYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjQPXlKSzVyPUCuNFQ1PDdizszN MULTRW5ITVJ?
MEL-JUSO NWn4XVNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTyRoRKSzVyPUCuNFQ1PzVizszN NWjLe5BiW0GQR1XS
BT-474 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMES1JO69VQ>? MYPTRW5ITVJ?
CaR-1 NWjFbZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL1c4tZUUN3ME2wMlA1PTR7IN88US=> NVrHeI9iW0GQR1XS
PSN1 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMES2NFMh|ryP MWrTRW5ITVJ?
KYSE-510 M{XCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKyTWM2OD1yLkC0OlQ6KM7:TR?= NH;PeWRUSU6JRWK=
KP-4 NXLreWg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\nVmN{UUN3ME2wMlA1PzV|IN88US=> NH3zcWxUSU6JRWK=
KYSE-410 NXX3XGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLnTWM2OD1yLkC0O|czKM7:TR?= Mmm4V2FPT0WU
G-402 NGHrUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiwTWM2OD1yLkC0O|g6KM7:TR?= NXP4cmZTW0GQR1XS
DOK M3HLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTnTWM2OD1yLkC0PVAzKM7:TR?= M1jCSnNCVkeHUh?=
COR-L88 NV;sUHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMES5NVIh|ryP MnXwV2FPT0WU
SKG-IIIa NXnpR242T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKxTWM2OD1yLkC0PVg3KM7:TR?= NIrYRY1USU6JRWK=
AN3-CA M2i3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjnOnRjUUN3ME2wMlA2KM7:TR?= MWHTRW5ITVJ?
SW48 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEWwN|kh|ryP MmX4V2FPT0WU
YKG-1 M1z3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPQO3RmUUN3ME2wMlA2ODdzIN88US=> NEGyVVZUSU6JRWK=
KYSE-150 NX\4e|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEWyN|Uh|ryP MXjTRW5ITVJ?
HuO-3N1 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMEWyN|ch|ryP MV\TRW5ITVJ?
LB1047-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX0XmhKSzVyPUCuNFUzQTZizszN M4r4WXNCVkeHUh?=
NCI-H2030 NFy4RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjjZlVKSzVyPUCuNFU1OTRizszN NGP0UWpUSU6JRWK=
YH-13 NGHx[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XvUWlEPTB;MD6wOVczOiEQvF2= MlX0V2FPT0WU
5637 M2nYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[2TWM2OD1yLkC1O|Qh|ryP MYjTRW5ITVJ?
LOXIMVI M2XqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:3cllKSzVyPUCuNFU5PzJizszN NUjxUXR3W0GQR1XS
GT3TKB MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjLc2dsUUN3ME2wMlA2QTR{IN88US=> NWLMR5dKW0GQR1XS
TCCSUP M{Die2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPTWM2OD1yLkC1PVY1KM7:TR?= NGC5Uo1USU6JRWK=
EPLC-272H MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0TWM2OD1yLkC2NlA2KM7:TR?= MnKzV2FPT0WU
LU-99A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTvUIZVUUN3ME2wMlA3OjN5IN88US=> MX3TRW5ITVJ?
NCI-H1755 NVr5Sm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ToOWlEPTB;MD6wOlM1OSEQvF2= MnnhV2FPT0WU
KM12 NFXYRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDVHRKSzVyPUCuNFY{PDhizszN M13u[XNCVkeHUh?=
SF295 M2W4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrSTWM2OD1yLkC2OFUzKM7:TR?= MmnVV2FPT0WU
MZ2-MEL M4DrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[3RmJzUUN3ME2wMlA3PTV|IN88US=> MUPTRW5ITVJ?
HEC-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C2dGlEPTB;MD6wOlU5QCEQvF2= NYLqdldkW0GQR1XS
SW684 NHn6VWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHjTWM2OD1yLkC2OVkyKM7:TR?= NH;DNVdUSU6JRWK=
SF539 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwME[2PFEh|ryP NEfac5pUSU6JRWK=
GMS-10 NWHJPHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT3bY5KUUN3ME2wMlA3Pjl7IN88US=> M2Dx[nNCVkeHUh?=
MV-4-11 M4XJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFztVIhKSzVyPUCuNFY5ODNizszN NUHtPGRiW0GQR1XS
HT-29 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfxcXpKSzVyPUCuNFY6OTlizszN Mmi1V2FPT0WU
23132-87 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr1TWM2OD1yLkC2PVUh|ryP NV\ndHBFW0GQR1XS
SW620 NITLZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzEd|VKSzVyPUCuNFcxOjZizszN MknHV2FPT0WU
HCC1806 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn2Ro83UUN3ME2wMlA4OTNzIN88US=> M2X0TXNCVkeHUh?=
Hs-578-T NWfWR2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzxTWM2OD1yLkC3NlA5KM7:TR?= MW\TRW5ITVJ?
A2058 NXjycGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECxc|NKSzVyPUCuNFczOjhizszN Mmf5V2FPT0WU
MEL-HO NFH1NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrkNlYyUUN3ME2wMlA4OjV3IN88US=> NUXMbFFKW0GQR1XS
HCC2998 NIDkZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjsTWM2OD1yLkC3N|Q4KM7:TR?= NIKyTIpUSU6JRWK=
HuO9 M1jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG1c4hjUUN3ME2wMlA4PTh7IN88US=> NIPVb3pUSU6JRWK=
CAL-39 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftTooyUUN3ME2wMlA4PzZ4IN88US=> NULBToNFW0GQR1XS
M14 NXnTSoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEe5NVMh|ryP MYjTRW5ITVJ?
BFTC-909 M1T1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3HdFJKSzVyPUCuNFc6PjlizszN NEXET2lUSU6JRWK=
TE-11 M2HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzrS41KSzVyPUCuNFc6QTZizszN MUjTRW5ITVJ?
TGBC1TKB MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrGNGVKSzVyPUCuNFgxPDNizszN NFfjeW1USU6JRWK=
L-363 NWT2OHBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnRWlEPTB;MD6wPFIxPiEQvF2= NWHMfGdTW0GQR1XS
A431 NEPsUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;TRWlEPTB;MD6wPFIyKM7:TR?= M1:4ZnNCVkeHUh?=
MKN45 NWSwZXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEiyNVkh|ryP M{\WdXNCVkeHUh?=
HT-1080 NH\XRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TMUGlEPTB;MD6wPFQ{QSEQvF2= MljoV2FPT0WU
OVCAR-8 M3\GNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEi2NlIh|ryP NVHnWlRQW0GQR1XS
LCLC-97TM1 NWXhPHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fpW2lEPTB;MD6wPFczQCEQvF2= NUixSZlKW0GQR1XS
M059J MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjmTWM2OD1yLkC5NFI4KM7:TR?= MUXTRW5ITVJ?
SK-MEL-2 NXjBcJNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrz[G5{UUN3ME2wMlA6ODZizszN NHXaWoFUSU6JRWK=
TE-1 NILId2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXEO2FKSzVyPUCuNFkzODRizszN NV2xRXFQW0GQR1XS
KYSE-180 NF7JendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjiV|VKSzVyPUCuNFkzPjJizszN MorpV2FPT0WU
D-247MG M3;K[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfLbIViUUN3ME2wMlA6PDV3IN88US=> MYrTRW5ITVJ?
8-MG-BA M{PLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf5TWM2OD1yLkC5OFczKM7:TR?= MmjDV2FPT0WU
NCI-H1792 M1H1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS2PJBmUUN3ME2wMlA6PjF6IN88US=> MnHyV2FPT0WU
MCF7 M2PNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEm2O|ch|ryP NIjCVFJUSU6JRWK=
NCI-H2122 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\wTFNKSzVyPUCuNFk4PDVizszN M3zQUHNCVkeHUh?=
EFO-27 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEm5PVch|ryP NWD3bGhKW0GQR1XS
LB2241-RCC NH3pXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHMTWM2OD1yLkGwNFU1KM7:TR?= M1LUWnNCVkeHUh?=
SN12C NEjmR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e1VGlEPTB;MD6xNFExPyEQvF2= MXLTRW5ITVJ?
A498 M2HKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzGVpZsUUN3ME2wMlExOThizszN NWTpepFPW0GQR1XS
PANC-03-27 M1LSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV61NY9FUUN3ME2wMlExOjh4IN88US=> NYfRRpE{W0GQR1XS
NCI-H1581 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nvS2lEPTB;MD6xNFI6KM7:TR?= NXzY[GY{W0GQR1XS
U-87-MG NVL1[IFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH64coxKSzVyPUCuNVA{ODdizszN MUTTRW5ITVJ?
G-401 M1npOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XXPWlEPTB;MD6xNFM2OyEQvF2= NF;XfZVUSU6JRWK=
SiHa MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;POG1OUUN3ME2wMlExPDh4IN88US=> MoTFV2FPT0WU
U251 NHPSOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMUC1NlUh|ryP M{\Kd3NCVkeHUh?=
MMAC-SF MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX3ZYhXUUN3ME2wMlExPTNzIN88US=> M17QcHNCVkeHUh?=
BB65-RCC M{\MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnR[oRKSzVyPUCuNVA2PTRizszN M3;Nb3NCVkeHUh?=
NKM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvFNWtWUUN3ME2wMlExPjZ4IN88US=> MUXTRW5ITVJ?
HD-MY-Z MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6zUFkxUUN3ME2wMlExQDd|IN88US=> M1ewVXNCVkeHUh?=
TGBC11TKB M2DSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TnT2lEPTB;MD6xNFkxOyEQvF2= Ml3xV2FPT0WU
COLO-679 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUGyNVEh|ryP MYHTRW5ITVJ?
TE-8 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMUGyOlQh|ryP NX60[o9SW0GQR1XS
SK-MEL-28 M2HRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\3TWM2OD1yLkGxN|IyKM7:TR?= MkLUV2FPT0WU
SH-4 M2mwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUGzOVYh|ryP Mn3xV2FPT0WU
KALS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjuTWM2OD1yLkGxN|k{KM7:TR?= M1\JdHNCVkeHUh?=
RKO M13qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPXXoNvUUN3ME2wMlEyPzZ2IN88US=> MXvTRW5ITVJ?
OMC-1 NFv0XZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvuTVBKSzVyPUCuNVE4QTdizszN MnrWV2FPT0WU
BT-549 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMUG3PVkh|ryP M1PIenNCVkeHUh?=
NCI-H28 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnKUJRKSzVyPUCuNVE5OTdizszN M3rOPHNCVkeHUh?=
RXF393 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2fmlEPTB;MD6xNVk5OiEQvF2= MXzTRW5ITVJ?
COLO-829 NETKZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUKwNFUh|ryP NFL0e5JUSU6JRWK=
HMV-II M2TMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO4SIVQUUN3ME2wMlEzODJizszN NXzlOm9QW0GQR1XS
SW1990 NE[2RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjDdYZKSzVyPUCuNVIyPTdizszN M3GwfHNCVkeHUh?=
NCI-H1437 NFLUV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i5T2lEPTB;MD6xNlE2PyEQvF2= MVzTRW5ITVJ?
SNB75 NVq0cVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfJSndKSzVyPUCuNVIyPjlizszN M1PLRXNCVkeHUh?=
EW-3 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\CTWM2OD1yLkGyOlYyKM7:TR?= NVHXUok{W0GQR1XS
SAS NGjObmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMUK2PUDPxE1? MnHsV2FPT0WU
NCI-H1666 NXvT[HRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mxemlEPTB;MD6xNlc4PCEQvF2= Mn7qV2FPT0WU
A375 NYfWSYRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5dm9tUUN3ME2wMlEzPzd6IN88US=> NWnQVoFLW0GQR1XS
CAMA-1 NETQb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PadWlEPTB;MD6xNlkzPCEQvF2= NHmz[VZUSU6JRWK=
HuP-T4 M2f0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHxd|dTUUN3ME2wMlEzQTR|IN88US=> MnT2V2FPT0WU
NCI-H292 NHjn[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHFTWM2OD1yLkGzNVEh|ryP M1X0NHNCVkeHUh?=
PC-14 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMUOyNVEh|ryP NFX4XGtUSU6JRWK=
BPH-1 NHzBfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMUO0NUDPxE1? MmexV2FPT0WU
GAK NELoUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\3VoJKSzVyPUCuNVM2PjdizszN NXmwbYN7W0GQR1XS
VMRC-RCZ MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfwUmlKSzVyPUCuNVM4PjJizszN NIDZN|VUSU6JRWK=
SK-MEL-24 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD1yLkGzPFch|ryP M4XjPHNCVkeHUh?=
LB831-BLC NVLmT2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XZc2lEPTB;MD6xN|g5OyEQvF2= NGXjVpNUSU6JRWK=
NCI-H2452 NHzKR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7rTWM2OD1yLkGzPVU3KM7:TR?= NFL0TW1USU6JRWK=
RT-112 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nTOWlEPTB;MD6xOFA{PSEQvF2= NV2wfYhIW0GQR1XS
GP5d M3W5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4ZZpKSzVyPUCuNVQyODRizszN M1;YVXNCVkeHUh?=
LC-2-ad Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M12zPWlEPTB;MD6xOFEzOSEQvF2= Mn\BV2FPT0WU
MPP-89 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zvbGlEPTB;MD6xOFEzPSEQvF2= MkDOV2FPT0WU
NUGC-3 M2LkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMUS0O|gh|ryP NUjZTYw2W0GQR1XS
GI-1 NX\hNWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfyTWM2OD1yLkG0OVU5KM7:TR?= NWjBTmtJW0GQR1XS
HCC1419 M3G1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMUS1O|Yh|ryP MmfEV2FPT0WU
SW1573 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TjS2lEPTB;MD6xOFc2QCEQvF2= NUjUT5hpW0GQR1XS
NCI-H2347 NGDlPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj4TWM2OD1yLkG0PFM6KM7:TR?= NFHMUpNUSU6JRWK=
Mewo NULNTVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMUS4PFkh|ryP MnrmV2FPT0WU
639-V NGDxO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMUWwNVMh|ryP NGS4NIVUSU6JRWK=
AsPC-1 NFG4R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHToT2tKSzVyPUCuNVUzOjVizszN NXLXUZFFW0GQR1XS
NCI-H1648 NGLjU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS5TWM2OD1yLkG1NlMzKM7:TR?= MXjTRW5ITVJ?
786-0 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfIXHF1UUN3ME2wMlE2OzhzIN88US=> NYjFeY43W0GQR1XS
ETK-1 M1fjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMUW5JO69VQ>? MYPTRW5ITVJ?
BxPC-3 NF[2OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HXTWlEPTB;MD6xOVk3PiEQvF2= MWnTRW5ITVJ?
CAL-62 NWW2UIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3CTWM2OD1yLkG2NVY6KM7:TR?= M1\PVHNCVkeHUh?=
HCC1937 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjWS4FXUUN3ME2wMlE3Ojd3IN88US=> MlLDV2FPT0WU
NCI-H1299 NXPNUotZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;iOXBKSzVyPUCuNVYzQDVizszN NEDKfZBUSU6JRWK=
SW1088 NGLoU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMU[0NVMh|ryP NF\NPXhUSU6JRWK=
FTC-133 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMU[1OEDPxE1? MY\TRW5ITVJ?
OC-314 NHq2WmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMU[2PUDPxE1? MU\TRW5ITVJ?
SCC-9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPkTWM2OD1yLkG2O|E3KM7:TR?= Mn;MV2FPT0WU
HT-1376 M3PGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMU[5N|Yh|ryP MYjTRW5ITVJ?
U-2-OS MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULQPWk2UUN3ME2wMlE4OTd|IN88US=> Mme4V2FPT0WU
COLO-824 M{fhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3mTWM2OD1yLkG3Nlk1KM7:TR?= NVfNfXMyW0GQR1XS
BB30-HNC MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHhV25KSzVyPUCuNVc{OyEQvF2= Mn\YV2FPT0WU
NCI-H2087 NYXVXIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMUezOlgh|ryP MV3TRW5ITVJ?
NCI-H2170 M2X1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\VTWM2OD1yLkG3OVM3KM7:TR?= M1;GT3NCVkeHUh?=
SK-OV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPV[mNKSzVyPUCuNVc2PzFizszN NYPmfmJvW0GQR1XS
MZ7-mel MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXRcW1FUUN3ME2wMlE4PjR7IN88US=> M{PCcXNCVkeHUh?=
NCI-H650 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUe2PFIh|ryP Mm\JV2FPT0WU
KOSC-2 M2PvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jWRWlEPTB;MD6xO|c{PCEQvF2= M4jnbXNCVkeHUh?=
SCC-4 NXPiSW1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni5TWM2OD1yLkG3O|c4KM7:TR?= MlnEV2FPT0WU
MDA-MB-157 NF;RVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zJVGlEPTB;MD6xPFA5OiEQvF2= Mn;CV2FPT0WU
KYSE-520 NYTvNYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMUiyJO69VQ>? MlHSV2FPT0WU
LK-2 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUizNFMh|ryP MkPSV2FPT0WU
KNS-81-FD NILuTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fvOWlEPTB;MD6xPFM6PCEQvF2= M1LPcXNCVkeHUh?=
IGROV-1 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M362XmlEPTB;MD6xPFQ1OyEQvF2= MUnTRW5ITVJ?
DEL MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K2W2lEPTB;MD6xPFQ2KM7:TR?= NFW0OopUSU6JRWK=
NCI-H1395 NF7EXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXPfmt6UUN3ME2wMlE5Pjh{IN88US=> MXzTRW5ITVJ?
JEG-3 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMUi3NFUh|ryP MmXrV2FPT0WU
BCPAP NWfaRYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH74T2pKSzVyPUCuNVg5PzJizszN NUT5bFFSW0GQR1XS
CAL-27 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfudoVKUUN3ME2wMlE6ODJ{IN88US=> MkTPV2FPT0WU
RD MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMUmxNVMh|ryP Ml[zV2FPT0WU
RVH-421 Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPVXJlKSzVyPUCuNVkyOTZizszN NWDR[G5sW0GQR1XS
Capan-2 NYnFbJR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMUmyOVYh|ryP MYXTRW5ITVJ?
COLO-680N M3;kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMUmzOlQh|ryP MoLrV2FPT0WU
NCI-H1650 NYqwfHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:3bmlEPTB;MD6yNFA2PyEQvF2= NUHVR4Z2W0GQR1XS
SBC-5 NWnMPHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X2OmlEPTB;MD6yNFEyQCEQvF2= NVP4U4tUW0GQR1XS
U031 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMkC1OFch|ryP M2XFSHNCVkeHUh?=
S-117 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrHbINNUUN3ME2wMlIxPTZ2IN88US=> NYfhV4tGW0GQR1XS
DoTc2-4510 M2D0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMkC3Olkh|ryP NGrFNZFUSU6JRWK=
AM-38 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\jfWlEPTB;MD6yNFg1QCEQvF2= MXPTRW5ITVJ?
A172 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUN2lEPTB;MD6yNVAzOiEQvF2= MnjXV2FPT0WU
HPAF-II NGL0bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojVTWM2OD1yLkKxNlY1KM7:TR?= MYHTRW5ITVJ?
769-P M1foPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMkGyPEDPxE1? NULS[2xjW0GQR1XS
MFE-280 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvDe3VDUUN3ME2wMlIyOjl6IN88US=> NFLjSWRUSU6JRWK=
TE-9 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMkG3PFYh|ryP NET3T5JUSU6JRWK=
C2BBe1 NGn4O2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TtfGlEPTB;MD6yNlE6KM7:TR?= NYXtOZBnW0GQR1XS
EoL-1-cell NF63NJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMkKyNFMh|ryP MnrQV2FPT0WU
G-361 NVrqflJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX1VXlbUUN3ME2wMlIzPjh{IN88US=> MXjTRW5ITVJ?
KYSE-270 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMkOwPFQh|ryP MVTTRW5ITVJ?
TK10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;nPXhKSzVyPUCuNlMyOTdizszN NEjJXlFUSU6JRWK=
ML-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLjdJFTUUN3ME2wMlI{OTF7IN88US=> M1fESXNCVkeHUh?=
MHH-ES-1 M37zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL5TWM2OD1yLkKzOlgyKM7:TR?= NEXEfnlUSU6JRWK=
BHY NWP0TVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMkO2PVEh|ryP M2PHe3NCVkeHUh?=
LS-513 M{jI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[2PGlEPTB;MD6yN|k3OSEQvF2= M33OUHNCVkeHUh?=
COLO-678 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\TOY5GUUN3ME2wMlI1ODR2IN88US=> NFSxXJJUSU6JRWK=
NCI-H747 NXzYeo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGexZWlKSzVyPUCuNlQyPjlizszN Mo\iV2FPT0WU
K5 M{LWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7RTWM2OD1yLkK0N|gh|ryP MlW5V2FPT0WU
OS-RC-2 M3zwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;HTWM2OD1yLkK0OVA6KM7:TR?= Ml;yV2FPT0WU
KINGS-1 M1nOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS3TWM2OD1yLkK0OVI6KM7:TR?= MWrTRW5ITVJ?
SCC-25 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\zTZNWUUN3ME2wMlI1PTZ|IN88US=> NGPjTVdUSU6JRWK=
CAPAN-1 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fpXWlEPTB;MD6yOFc5OyEQvF2= MYTTRW5ITVJ?
ESS-1 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHMU5h4UUN3ME2wMlI1QDB3IN88US=> MorEV2FPT0WU
TE-6 NG\OeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X2XGlEPTB;MD6yOVc2KM7:TR?= NUXGfmFVW0GQR1XS
LB2518-MEL NHfDNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMkW3O|ch|ryP NYDId|V[W0GQR1XS
COLO-800 NUfyXJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXLSIlKSzVyPUCuNlU5OTJizszN Mo\kV2FPT0WU
LU-134-A M3XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT4TWM2OD1yLkK2NVM3KM7:TR?= NH;xeYtUSU6JRWK=
NCI-H1155 NHrmRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr6TWM2OD1yLkK2NVYzKM7:TR?= MljFV2FPT0WU
MFM-223 NGH4VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfiZmtKSzVyPUCuNlY{PjNizszN MV;TRW5ITVJ?
HTC-C3 M4HBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMk[1NFYh|ryP M1znV3NCVkeHUh?=
HCT-116 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMk[1PVkh|ryP NHrieYFUSU6JRWK=
Ca-Ski MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n3cmlEPTB;MD6yOlY4QCEQvF2= NWf3Sog6W0GQR1XS
SBC-1 NWPxbmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PkcWlEPTB;MD6yOlc1OiEQvF2= MlzLV2FPT0WU
NB69 M1:4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\5TmtQUUN3ME2wMlI4ODh5IN88US=> NVLBVoFWW0GQR1XS
J82 NGHX[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvYTWM2OD1yLkK3NlY2KM7:TR?= MnrpV2FPT0WU
U-118-MG M{Cz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiyTWM2OD1yLkK3OVc6KM7:TR?= MVHTRW5ITVJ?
NCI-H1355 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMkiwO|Qh|ryP M{X1bHNCVkeHUh?=
NCI-H1048 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL2TWM2OD1yLkK4PVU3KM7:TR?= M17Zd3NCVkeHUh?=
SW954 NGjiTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PnNmlEPTB;MD6yPVIzPyEQvF2= MXXTRW5ITVJ?
NMC-G1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLBbHFEUUN3ME2wMlI6Ojd5IN88US=> NGHXcGpUSU6JRWK=
SW1710 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHtcGRKSzVyPUCuNlk1QTRizszN NUO2ZVhDW0GQR1XS
KY821 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\BZWVKSzVyPUCuNlk5PzJizszN M3W3R3NCVkeHUh?=
HCC38 NFfyRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;GRWlEPTB;MD6zNFA4QCEQvF2= M3XsZ3NCVkeHUh?=
NCI-SNU-5 NGnDPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvyTWM2OD1yLkOwOVQh|ryP NFzub21USU6JRWK=
ES8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnvW4lKSzVyPUCuN|A4QDRizszN M2DleXNCVkeHUh?=
COLO-792 NFK4[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\i[2VCUUN3ME2wMlMyOjVzIN88US=> MofIV2FPT0WU
BFTC-905 M4\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP6TWM2OD1yLkOxOVIyKM7:TR?= M3XVUXNCVkeHUh?=
ChaGo-K-1 NFj2W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:0Ro4{UUN3ME2wMlMyPzF3IN88US=> NVGwOJg6W0GQR1XS
Daoy MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjwfmlKSzVyPUCuN|E4OjNizszN MV;TRW5ITVJ?
SJSA-1 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnzNZNxUUN3ME2wMlMyQDR5IN88US=> MojiV2FPT0WU
KNS-62 NIjNc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjUPZRKSzVyPUCuN|IxQDhizszN MV7TRW5ITVJ?
CAKI-1 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXmTWM2OD1yLkOyNVEyKM7:TR?= NFznNIhUSU6JRWK=
UACC-62 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwM{KyNlch|ryP Mn;UV2FPT0WU
HuCCT1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjqTWM2OD1yLkOyNlg{KM7:TR?= M2KycHNCVkeHUh?=
CTB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPaNHRKSzVyPUCuN|I4PTNizszN NG\CdotUSU6JRWK=
NTERA-S-cl-D1 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjaU2pKSzVyPUCuN|I5OzZizszN MoTkV2FPT0WU
T-24 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwM{OxOVkh|ryP NHSzTItUSU6JRWK=
KYSE-70 NX72R3dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\5fXBKSzVyPUCuN|MzQDNizszN MmTsV2FPT0WU
SW626 NUnxfoIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13nNmlEPTB;MD6zN|U{OiEQvF2= MkDJV2FPT0WU
LB996-RCC NGPMcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH5S4lKSzVyPUCuN|M3OTlizszN M136cHNCVkeHUh?=
DMS-273 NXTxclM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTpcZV1UUN3ME2wMlM{QTF4IN88US=> NWrkWoNoW0GQR1XS
SW1783 NEPMcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwM{O5PVch|ryP M{XORnNCVkeHUh?=
KU812 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfJ[nk4UUN3ME2wMlM1ODN6IN88US=> MUXTRW5ITVJ?
HSC-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwM{SwOVMh|ryP Ml;aV2FPT0WU
A3-KAW M2\Ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\HWG9uUUN3ME2wMlM1OTZ{IN88US=> NYXPc5FHW0GQR1XS
COLO-684 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTWfnlQUUN3ME2wMlM1PTBzIN88US=> Mn3YV2FPT0WU
NCI-H2405 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOyUVRKSzVyPUCuN|Q3OzFizszN M1flVHNCVkeHUh?=
NCI-H2228 M3jjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPTTIIyUUN3ME2wMlM2OzV5IN88US=> Mnf6V2FPT0WU
NB13 NYS2WHFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfLXoxOUUN3ME2wMlM3QDJ7IN88US=> MYXTRW5ITVJ?
no-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO2TWM2OD1yLkO2PVUh|ryP MWjTRW5ITVJ?
DK-MG NV3aU|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED4XJlKSzVyPUCuN|cyQDhizszN Ml\NV2FPT0WU
NBsusSR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[wTWM2OD1yLkO3Nlg2KM7:TR?= M1jVUnNCVkeHUh?=
KP-N-YS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\6TWM2OD1yLkO3OFY{KM7:TR?= MUPTRW5ITVJ?
CFPAC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwM{e1NVgh|ryP NHe3ZoVUSU6JRWK=
KARPAS-45 NILSXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwM{e4OlIh|ryP NFHyeolUSU6JRWK=
NCI-H1793 NVP0VldnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwM{i1NUDPxE1? M1[0NXNCVkeHUh?=
HCE-T NWTIXllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zhOmlEPTB;MD6zPFYxOyEQvF2= MWLTRW5ITVJ?
NCI-H520 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXZTIU{UUN3ME2wMlM5PzB|IN88US=> NIizNWlUSU6JRWK=
HCC2157 NWfyb3k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\o[IdKSzVyPUCuN|g4QDFizszN MWfTRW5ITVJ?
EW-18 NEDlcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\GcWlEPTB;MD6zPFk1OSEQvF2= NVnoOIJJW0GQR1XS
RO82-W-1 M3rTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nKUmlEPTB;MD6zPVY6QSEQvF2= NHzQSnJUSU6JRWK=
HuP-T3 NFPz[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvkTWM2OD1yLkSwNVQ{KM7:TR?= NEWxfY1USU6JRWK=
PANC-10-05 NHTDSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j1UmlEPTB;MD60NVE4KM7:TR?= MljJV2FPT0WU
NCI-H1703 NFTCfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrUeZdSUUN3ME2wMlQyPDR4IN88US=> M2rOPXNCVkeHUh?=
TE-10 NE\xTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7SRVRTUUN3ME2wMlQyPDR5IN88US=> NWWyWoNFW0GQR1XS
HOS NVX2O2F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrCTWM2OD1yLkSxOlgzKM7:TR?= MojJV2FPT0WU
LN-405 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvtTWM2OD1yLkSxOlg4KM7:TR?= MULTRW5ITVJ?
A427 M17KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HxbWlEPTB;MD60NVk5OSEQvF2= M2qzTnNCVkeHUh?=
CAL-12T NUDnfYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknITWM2OD1yLkSyO|gh|ryP NHfXd3hUSU6JRWK=
SW756 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNESxPFMh|ryP NUDocnY4W0GQR1XS
YAPC MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPpTWM2OD1yLkS1NFgh|ryP M3X0T3NCVkeHUh?=
GOTO MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwNEWxOkDPxE1? MVnTRW5ITVJ?
C3A NXX0dnhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;LSIp{UUN3ME2wMlQ2PDN5IN88US=> NVfDcnhYW0GQR1XS
UM-UC-3 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNEW0O{DPxE1? NXf6UFdWW0GQR1XS
NCI-H1573 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwNEW1Olkh|ryP Mn\3V2FPT0WU
LS-411N MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfFeYN[UUN3ME2wMlQ3PTJ5IN88US=> MWrTRW5ITVJ?
COR-L23 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f0W2lEPTB;MD60Olc3PCEQvF2= NXPqeld5W0GQR1XS
HCE-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnxUY9HUUN3ME2wMlQ4PDR4IN88US=> M1mzN3NCVkeHUh?=
NCI-H2291 NF[0WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwNEe4PVYh|ryP MVjTRW5ITVJ?
A101D NYCyNIVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwNEiwOVMh|ryP NWD4c2hZW0GQR1XS
HT-3 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v3RWlEPTB;MD60PFIyPyEQvF2= MVHTRW5ITVJ?
HOP-62 NYnEPGlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jueGlEPTB;MD60PVg3PSEQvF2= MX\TRW5ITVJ?
PC-3 NVPXVVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrjb5BoUUN3ME2wMlUyPTB5IN88US=> MUTTRW5ITVJ?
CTV-1 NVHhPXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTqTWM2OD1yLkWyOlY6KM7:TR?= NWHMZ4FGW0GQR1XS
PANC-08-13 M33VdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DOe2lEPTB;MD61N|E4PyEQvF2= MmfDV2FPT0WU
CAL-120 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNUOzPVkh|ryP MXjTRW5ITVJ?
UMC-11 NXTYPIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXZTHFKSzVyPUCuOVUzOzRizszN NFrt[mFUSU6JRWK=
MSTO-211H MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfvd3pKSzVyPUCuOVU4PjJizszN MWLTRW5ITVJ?
NCI-H2126 NUTibJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS0VXFUUUN3ME2wMlU3QDF3IN88US=> MYDTRW5ITVJ?
SNU-C2B MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG1U4JKSzVyPUCuOVc6PzdizszN MX7TRW5ITVJ?
DBTRG-05MG NF7KbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSzTWM2OD1yLkW4NFU{KM7:TR?= MWXTRW5ITVJ?
MKN1 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNUi3PFMh|ryP MXzTRW5ITVJ?
ES3 NIXncVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DBTmlEPTB;MD61PVEzPCEQvF2= M1\wfXNCVkeHUh?=
OVCAR-3 NGWxN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\qSJQ{UUN3ME2wMlU6OzRzIN88US=> NXvXd4JEW0GQR1XS
ACHN MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4S49RUUN3ME2wMlYxPTZ7IN88US=> MkPFV2FPT0WU
SW872 NEH0emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrJTWM2OD1yLk[wO|Y{KM7:TR?= MXzTRW5ITVJ?
CP66-MEL M4DPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDxTWM2OD1yLk[wPVY6KM7:TR?= MlrYV2FPT0WU
NCI-H661 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf0fHY{UUN3ME2wMlYyOTB2IN88US=> MWrTRW5ITVJ?
UACC-893 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XiZ2lEPTB;MD62N|Y5OSEQvF2= NECz[WtUSU6JRWK=
JVM-3 NU\0WpVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNkO4NFQh|ryP M1fOOnNCVkeHUh?=
SF268 NUeyVFI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNkSzOFkh|ryP MYPTRW5ITVJ?
OCI-AML2 M3W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHDOHdKSzVyPUCuOlU{QTdizszN MnPuV2FPT0WU
RPMI-8226 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\VN2lEPTB;MD62OlMzOyEQvF2= NEPxXXJUSU6JRWK=
MKN28 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK2e|Y1UUN3ME2wMlY3PjJ2IN88US=> M{O5d3NCVkeHUh?=
MDA-MB-453 M2\wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq4TWM2OD1yLk[3NVgh|ryP NEDtWVRUSU6JRWK=
BV-173 M2rNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwNki2O|kh|ryP M3ztPXNCVkeHUh?=
NCI-H358 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNki3NlYh|ryP MWnTRW5ITVJ?
NCI-H1651 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3FV5d4UUN3ME2wMlch|ryP NHnncXRUSU6JRWK=
MDA-MB-415 NV;rWoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4cYZZUUN3ME2wMlcxQDJ7IN88US=> MUTTRW5ITVJ?
8305C MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[5cZVKSzVyPUCuO|I1QThizszN M4LlcnNCVkeHUh?=
EFM-19 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq0TWM2OD1yLkezOlcyKM7:TR?= MkHLV2FPT0WU
RERF-LC-MS M3LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7FV244UUN3ME2wMlc1PjF|IN88US=> NVfyTWtwW0GQR1XS
A388 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLV[G45UUN3ME2wMlc3PDZ5IN88US=> M2HSbHNCVkeHUh?=
GI-ME-N M2mzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H4OWlEPTB;MD63O|I{PSEQvF2= NWK0VIZFW0GQR1XS
IGR-1 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nZZWlEPTB;MD63PVA1OyEQvF2= Ml;MV2FPT0WU
LNCaP-Clone-FGC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf5SVA3UUN3ME2wMlgxODB2IN88US=> MXPTRW5ITVJ?
SK-MEL-3 NHnnXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwOEG1NFgh|ryP MnHwV2FPT0WU
UACC-257 NHy0NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDmTWM2OD1yLkiyNlMyKM7:TR?= NXTIPVRZW0GQR1XS
OE33 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrKN3ZKSzVyPUCuPFUyODFizszN M1rSWnNCVkeHUh?=
QIMR-WIL NULmPW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwOEWxOFEh|ryP NXLreZM{W0GQR1XS
NCI-H2009 M3rHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1npZ2lEPTB;MD64OVMyOSEQvF2= NIXzfXNUSU6JRWK=
NCI-H522 M3m2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHLfXp2UUN3ME2wMlg4Pzh|IN88US=> Ml\CV2FPT0WU
Saos-2 NF\xOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDuTWM2OD1yLki3PFcyKM7:TR?= M1r4OXNCVkeHUh?=
NB17 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXCWY5tUUN3ME2wMlg5ODJ3IN88US=> NETMeZlUSU6JRWK=
D-392MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwOEmzOVYh|ryP NFqyUINUSU6JRWK=
SHP-77 NHzYVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwOUC0PFUh|ryP NIL5O49USU6JRWK=
SK-MEL-30 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvkTo83UUN3ME2wMlkyOTh3IN88US=> NGrPcZpUSU6JRWK=
GCIY NHLqdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfqRnJKSzVyPUCuPVE5PDNizszN MojBV2FPT0WU
HCC70 NUPlbnZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqyNWxKSzVyPUCuPVIxPTlizszN MoDIV2FPT0WU
LU-65 NXq0Rot5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jlUGlEPTB;MD65NlU6OSEQvF2= NEHRXI1USU6JRWK=
NCI-H1563 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTpXWdKSzVyPUCuPVQ5PjVizszN M37WSnNCVkeHUh?=
KURAMOCHI NWnOeHV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Hhd2lEPTB;MD65OVE6OiEQvF2= M2LreHNCVkeHUh?=
PA-1 M{fjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwOUW0NlQh|ryP MXLTRW5ITVJ?
NOS-1 NWeweJh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\PdJd2UUN3ME2wMlk4PDh7IN88US=> MWLTRW5ITVJ?
NCI-H69 M1v3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwOUe2N|Qh|ryP MoPYV2FPT0WU
KYSE-450 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP1OVdZUUN3ME2wMlk5PjJ4IN88US=> NWjxNmh5W0GQR1XS
8505C NWjlR4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;PZVlIUUN3ME2wMlk6QTh{IN88US=> MonlV2FPT0WU
TGBC24TKB NHvYO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO2TWM2OD1zLkCwNFg1KM7:TR?= MmLMV2FPT0WU
PFSK-1 NEjoUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwMEG0Nlgh|ryP NHTWeFlUSU6JRWK=
EKVX NYLjUlF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7tSWFKSzVyPUGuNFMyOjFizszN M1TLTnNCVkeHUh?=
RCM-1 NVTjNZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\STWM2OD1zLkC1OVA4KM7:TR?= NEPafppUSU6JRWK=
SW900 NGf3R4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwMEe4N{DPxE1? NFPJXZhUSU6JRWK=
D-542MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPMTWM2OD1zLkC3PFU2KM7:TR?= MX\TRW5ITVJ?
SK-PN-DW NWewTpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW4TWM2OD1zLkGwNFU3KM7:TR?= MoPwV2FPT0WU
NCI-H727 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDPTWM2OD1zLkGwNVU1KM7:TR?= Mlq5V2FPT0WU
SW837 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7rTWM2OD1zLkGwPVU1KM7:TR?= MorJV2FPT0WU
BT-20 NX\wbFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrVTWM2OD1zLkGxNlA1KM7:TR?= M3n2SnNCVkeHUh?=
RH-18 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H0cmlEPTB;MT6xN|ExOyEQvF2= MmnuV2FPT0WU
TE-12 NGjIXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Yd5dXUUN3ME2xMlE{OzN|IN88US=> MYfTRW5ITVJ?
NB10 NXW0Um4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLjTWM2OD1zLkGzN|Q1KM7:TR?= MoX3V2FPT0WU
AU565 NH7LcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwMUW5O|Mh|ryP NEXnTI5USU6JRWK=
OAW-42 NUm4TmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPTTWM2OD1zLkG4N|A3KM7:TR?= M2nFUHNCVkeHUh?=
DJM-1 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwMUm4PFEh|ryP NV2wUlZZW0GQR1XS
HH M3zDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkO4N|Eh|ryP NUDjfVJ2W0GQR1XS
LAMA-84 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHq[WZKSzVyPUGuNlc{QTRizszN Mkf0V2FPT0WU
KNS-42 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M370NGlEPTB;MT6zNFI6PiEQvF2= M2GwUnNCVkeHUh?=
NCI-H2052 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwM{C1NFch|ryP M{jT[HNCVkeHUh?=
MLMA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrWVJBsUUN3ME2xMlMzPDB5IN88US=> MUTTRW5ITVJ?
NB12 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHieGp{UUN3ME2xMlM2PjN4IN88US=> MUnTRW5ITVJ?
NCI-H1838 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyyUZBKSzVyPUGuN|Y{ODZizszN NIXFPJVUSU6JRWK=
NCI-H526 M1fOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f0[GlEPTB;MT6zO|g2OyEQvF2= NVfmV3o6W0GQR1XS
LS-123 NHWwToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzIZlBKSzVyPUGuN|kxQTRizszN M3rDVHNCVkeHUh?=
HDLM-2 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwM{myO|Eh|ryP MnjzV2FPT0WU
MC-IXC NV\HdWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WybGlEPTB;MT60NlM4OSEQvF2= MVLTRW5ITVJ?
HCT-15 M3Sw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTZNZJKSzVyPUGuOFMxPjhizszN NWm3Z4VOW0GQR1XS
NCI-H596 NXXwcIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\rVFdKSzVyPUGuOFUxPjFizszN NFHUeFlUSU6JRWK=
ZR-75-30 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnuTWM2OD1zLkS3NFgzKM7:TR?= NXTsTpg2W0GQR1XS
A704 NUPSXlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi2OXRqUUN3ME2xMlY3PTZ|IN88US=> M{f3fnNCVkeHUh?=
OVCAR-4 NETP[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PMbmlEPTB;MT62PVYxPyEQvF2= MnjvV2FPT0WU
SW1417 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwN{K4OFkh|ryP MUHTRW5ITVJ?
CAS-1 M3;0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XLOmlEPTB;MT63N|k{PiEQvF2= NFPibWdUSU6JRWK=
IST-SL1 M{jOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwN{m3OVkh|ryP MXrTRW5ITVJ?
A253 M1nMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHtRoZKSzVyPUGuPFIzOzlizszN MoDUV2FPT0WU
EW-16 NHTEcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6Z4ZPUUN3ME2xMlgzQDd3IN88US=> NF63eVdUSU6JRWK=
SK-NEP-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwOE[5PFgh|ryP NIXUXHJUSU6JRWK=
NCI-H226 NG\WT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O0SGlEPTB;MT64PVM2QSEQvF2= M13acXNCVkeHUh?=
HOP-92 NE\zOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\1TWM2OD1zLkm2NFk6KM7:TR?= NInxdWxUSU6JRWK=
NCI-H441 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTHUmtZUUN3ME2yMlAzOzN5IN88US=> M{Dh[XNCVkeHUh?=
LU-139 NX:3fJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwMEOxNVQh|ryP NVXFRXpkW0GQR1XS
SJRH30 NHjuN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy3dIY1UUN3ME2yMlA1OjV|IN88US=> M2fhSHNCVkeHUh?=
MG-63 NEnYV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELaZm1KSzVyPUKuNVQyOTFizszN MWHTRW5ITVJ?
NH-12 M37SPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwMUWwNFYh|ryP M2rmXHNCVkeHUh?=
NB7 M33xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwMUm2O|Mh|ryP MV7TRW5ITVJ?
LB771-HNC NFLlfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwMkC1PVUh|ryP NHzaVFFUSU6JRWK=
HCC1569 NGHnPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrQZoJWUUN3ME2yMlI1PTh|IN88US=> M3zXRnNCVkeHUh?=
D-283MED MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW4TWM2OD1{LkK0O|gzKM7:TR?= NECxTHhUSU6JRWK=
J-RT3-T3-5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HtZmlEPTB;Mj6yOVM2OSEQvF2= M3fwb3NCVkeHUh?=
ATN-1 NF;qZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWzPHdKSzVyPUKuN|MxQDJizszN MXzTRW5ITVJ?
HCC1954 NFzIWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTtTWM2OD1{LkO0OFA5KM7:TR?= NUX5NGtwW0GQR1XS
SCC-15 M2rmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW4NXlKSzVyPUKuN|k{OTJizszN M3z0PHNCVkeHUh?=
COLO-668 M{nvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwNEOyJO69VQ>? NXfIcWZ3W0GQR1XS
LB373-MEL-D MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv1TWM2OD1{LkW0Olc4KM7:TR?= Ml\nV2FPT0WU
no-10 NYHHeJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S5b2lEPTB;Mj61OFk1PyEQvF2= Mn7IV2FPT0WU
HT-1197 M3nLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvkSG1KSzVyPUKuOlMyQDhizszN MULTRW5ITVJ?
DU-145 M3XUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfITmRMUUN3ME2yMlc6OTZ{IN88US=> M3LWOHNCVkeHUh?=
SK-N-AS NUfhW4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOyfoxYUUN3ME2yMlg1Pjl{IN88US=> MY\TRW5ITVJ?
MOLT-4 NUD0dJA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwOEWzNlIh|ryP NGjPV3pUSU6JRWK=
EW-22 M4\lRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\rO3JKSzVyPUKuPVI5PDFizszN M37XUHNCVkeHUh?=
DB M2GyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKyT5o5UUN3ME2yMlk4PzV7IN88US=> NF\oSWlUSU6JRWK=
HL-60 NVy3VlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNwMESzO|Yh|ryP M1TsO3NCVkeHUh?=
SK-N-DZ M2nROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HJVGlEPTB;Mz6wOVA4PSEQvF2= NHy4dldUSU6JRWK=
NY M2H6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q4eGlEPTB;Mz6wPFU1OiEQvF2= MlPXV2FPT0WU
T47D NGDyT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwMUC1OVgh|ryP NXLu[|NsW0GQR1XS
NCI-H2029 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\NTWM2OD1|LkKyOFc4KM7:TR?= MmHlV2FPT0WU
KARPAS-299 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hOGlEPTB;Mz6yOlAzPyEQvF2= MVLTRW5ITVJ?
KM-H2 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwM{C2PEDPxE1? NVnsVItsW0GQR1XS
CHP-134 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwNEezPUDPxE1? MXHTRW5ITVJ?
22RV1 NIXhd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXKTWM2OD1|LkS5NVY5KM7:TR?= NFzFOXFUSU6JRWK=
NB5 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rUdWlEPTB;Mz61NFY5QSEQvF2= MY\TRW5ITVJ?
CW-2 NIPQO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m3b2lEPTB;Mz61OVMyPCEQvF2= MYjTRW5ITVJ?
EFO-21 NWXJb|M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XoRWlEPTB;Mz61Olk1KM7:TR?= MVPTRW5ITVJ?
HuH-7 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULqUpY6UUN3ME2zMlU5PDF2IN88US=> M4XlPXNCVkeHUh?=
ALL-PO MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T0S2lEPTB;Mz62NlM{PSEQvF2= MXTTRW5ITVJ?
EM-2 NFj4N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL6TWM2OD1|Lk[5NFEyKM7:TR?= M1TxSnNCVkeHUh?=
KLE NYjpUFRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf0TWM2OD1|LkezNFI6KM7:TR?= MYTTRW5ITVJ?
NEC8 M33MVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwOUG4NFgh|ryP MmP2V2FPT0WU
KP-N-YN M{f6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXTWM2OD1|LkmzOFc3KM7:TR?= NWKzU4RFW0GQR1XS
SK-MEL-1 M{DLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKzfFdKSzVyPUSuNFM2OThizszN MWDTRW5ITVJ?
CAL-54 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwMEW5NUDPxE1? M2\TPXNCVkeHUh?=
MS-1 NHO3b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnFboN2UUN3ME20MlE3OTV3IN88US=> M4K3PHNCVkeHUh?=
NCI-H209 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRwMkm5PVkh|ryP NHvoTJJUSU6JRWK=
NOMO-1 NGDSVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTkRmNKSzVyPUSuN|IyOzFizszN M1\VdnNCVkeHUh?=
RPMI-2650 NGTFSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRwM{[zNlch|ryP NWPNPXhbW0GQR1XS
NCI-H810 M1PZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRwM{m3N|Yh|ryP MnnvV2FPT0WU
Ca9-22 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSweFdKSzVyPUSuOFU3QTFizszN NWf2dpNUW0GQR1XS
ES4 NYe5fIRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL5[YFnUUN3ME20MlQ4ODl3IN88US=> M3X5eXNCVkeHUh?=
ES6 M3:zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\we2lEPTB;ND60PVY2PyEQvF2= M4[0PHNCVkeHUh?=
DMS-114 M3LVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTtb2kzUUN3ME20MlU1PjlzIN88US=> NVq4b2V7W0GQR1XS
ONS-76 NHjpUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjSOWRPUUN3ME20MlU4QTVizszN NF;DbGlUSU6JRWK=
K-562 M4Trc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwN{O4NVQh|ryP MXzTRW5ITVJ?
MHH-NB-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XLXWlEPTB;ND63OVQ3OSEQvF2= NI\ZZpRUSU6JRWK=
Calu-3 NEWx[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\nV4NKSzVyPUSuO|g2PDhizszN NEPSN|BUSU6JRWK=
HT55 NHfUXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwOES1OFUh|ryP NGG2TFNUSU6JRWK=
SK-N-FI M3q2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfXVpFKSzVyPUSuPFUxODlizszN MmrSV2FPT0WU
ES1 NF7xTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm2TWM2OD12Lki2NFU4KM7:TR?= MVTTRW5ITVJ?
SF126 NFr2bIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLmTWM2OD12LkmzNVg1KM7:TR?= NFTtdYlUSU6JRWK=
ES5 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rt[mlEPTB;NT6xNlQzPyEQvF2= M{faenNCVkeHUh?=
LoVo M2XYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPETWM2OD13LkG1PFcyKM7:TR?= NGO5V5JUSU6JRWK=
SNU-387 NYPiO4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fHXWlEPTB;NT6zNlM{QSEQvF2= NFnubFZUSU6JRWK=
C8166 NXLxUJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzSZmJKSzVyPUWuN|Y{OzlizszN Ml:xV2FPT0WU
LS-1034 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfC[2QyUUN3ME21MlQzOzB5IN88US=> NY\4dIlyW0GQR1XS
GR-ST NGTKTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3EWnBKSzVyPUWuOVIzODFizszN NXfRcFZCW0GQR1XS
NCI-H1092 NHf3[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wSIp7UUN3ME21MlczQDR|IN88US=> MVvTRW5ITVJ?
647-V MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq1WFR2UUN3ME21Mlc1PzB4IN88US=> NGn2TmZUSU6JRWK=
EW-13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTVwN{[2Nlch|ryP NUGwTIY4W0GQR1XS
KGN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC2TWM2OD14LkC5PVIyKM7:TR?= NY\1NFRrW0GQR1XS
D-423MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHRN2xiUUN3ME22MlQxOjh2IN88US=> MYDTRW5ITVJ?
ECC10 M2\YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC4eZh6UUN3ME23MlExOTBzIN88US=> MofGV2FPT0WU
TE-5 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\4cYZKSzVyPUeuOFEzQThizszN MnPhV2FPT0WU
P12-ICHIKAWA NUfjNWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO2W4dKSzVyPUeuOFU2OjNizszN NUPy[ZI1W0GQR1XS
NCI-H82 NGfDfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\qTWM2OD15LkS1O|AyKM7:TR?= M3fhe3NCVkeHUh?=
NCI-H1993 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTTdFkzUUN3ME23Mlg{ODZ|IN88US=> MkLUV2FPT0WU
RH-1 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\nb|ZKSzVyPUeuPFUzPDRizszN Mkj1V2FPT0WU
SW948 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[wS4ZKSzVyPUeuPVYxPDlizszN NETER2ZUSU6JRWK=
CAL-33 NGjaSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m0e2lEPTB;Nz65PVk{QCEQvF2= MXnTRW5ITVJ?
U-266 NX[1SI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TkeWlEPTB;OD6xOVc4PyEQvF2= MkDHV2FPT0WU
CAL-72 NELTOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojlTWM2OD16LkKwN|Ih|ryP NVjtR5ZlW0GQR1XS
SNU-423 NXKyO2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:4TWM2OD17LkO2OlY3KM7:TR?= MV3TRW5ITVJ?
KG-1 M4fyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDCe25KSzVyPUmuOVg1PTZizszN M{jpPHNCVkeHUh?=
HCC1395 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTifY1YUUN3ME25MlkzOzV{IN88US=> NVHNb4pJW0GQR1XS
BE-13 NX3Q[npzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rFdWlEPTB;MUCuPFg6OiEQvF2= NXjvdJNkW0GQR1XS
MKN7 NHPGO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH70RpRKSzVyPUGwMlk4PjVizszN NX;yWnk2W0GQR1XS
697 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFzLkG0O|Ih|ryP M3e2e3NCVkeHUh?=
LU-135 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\zd3JKSzVyPUGxMlI{ODdizszN M2q3bnNCVkeHUh?=
ES7 M1qwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XERWlEPTB;MUGuN|MyOyEQvF2= MonPV2FPT0WU
SK-HEP-1 NFHacoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFzLke2OFYh|ryP NXzIVIdHW0GQR1XS
BEN M4j4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7CTWM2OD1zMT64OVEh|ryP NHTvVYpUSU6JRWK=
NCI-H1770 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjOfIhKSzVyPUGyMlEzPiEQvF2= NELx[mRUSU6JRWK=
SW13 NVvwb4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\o[WlEPTB;MUKuNVU1OSEQvF2= MX;TRW5ITVJ?
MZ1-PC NFTvVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r3cWlEPTB;MUKuOVQ2OiEQvF2= NV\kZo5rW0GQR1XS
Mo-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TFbGlEPTB;MUKuO|QzOSEQvF2= MVHTRW5ITVJ?
HLE MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDD[VVrUUN3ME2xNk45OjF3IN88US=> NWfWZlN3W0GQR1XS
RCC10RGB NXvFTG86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjTW4tKSzVyPUGzMlY4OSEQvF2= NILlbYtUSU6JRWK=
COLO-320-HSR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnpO2VKSzVyPUGzMlc{QDFizszN MUPTRW5ITVJ?
BHT-101 NEflO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\yVphKSzVyPUGzMlg{PDVizszN NYfuUYc{W0GQR1XS
OCUB-M MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\6WIZKSzVyPUG0MlE3ODJizszN NUDRfoNQW0GQR1XS
MEG-01 NGDsPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTPb5UzUUN3ME2xOE4{PzB6IN88US=> Mn[xV2FPT0WU
RS4-11 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDTTWM2OD1zND63OFIh|ryP NFjKRWNUSU6JRWK=
MN-60 NUTqS2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPNTWM2OD1zND63PFk1KM7:TR?= MWHTRW5ITVJ?
NCI-H1304 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy2cIhMUUN3ME2xOU4xPDJ3IN88US=> NXe0WFl4W0GQR1XS
Ramos-2G6-4C10 NIHPNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonhTWM2OD1zNT6wOVgyKM7:TR?= NHLIW5JUSU6JRWK=
NCI-H2342 NX;DT3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[2[3pKSzVyPUG1MlIxPDRizszN MXvTRW5ITVJ?
LAN-6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLiTWM2OD1zNT60OFE1KM7:TR?= M3LpT3NCVkeHUh?=
JVM-2 NXz4PGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3LkW3OFgh|ryP MnXZV2FPT0WU
P30-OHK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILHc4NKSzVyPUG2MlA3OTRizszN MXvTRW5ITVJ?
C-33-A NYD1R29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7ncXRKSzVyPUG2MlYzOTRizszN M3HZenNCVkeHUh?=
RPMI-8866 M{e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLmNVZQUUN3ME2xOk45PDl4IN88US=> M1exUnNCVkeHUh?=
NCI-H630 M3rPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO4WYZKSzVyPUG2Mlg2OzdizszN NF\KNItUSU6JRWK=
KYSE-140 NXfZdYJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjYfJRKSzVyPUG3MlIxOjhizszN NULnVZZiW0GQR1XS
T84 NIOzfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[0SXUzUUN3ME2xPE45Pjl3IN88US=> MVvTRW5ITVJ?
KU-19-19 M1HxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D5V2lEPTB;MUiuPVYxQCEQvF2= MoDQV2FPT0WU
BALL-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDZTWM2OD1zOT6zN|k6KM7:TR?= MWLTRW5ITVJ?
Calu-6 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nwSmlEPTB;MUmuOFkzKM7:TR?= NIrKOVlUSU6JRWK=
EGI-1 NU[yeI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuwPVJKSzVyPUG5MlU6QCEQvF2= M3zEeHNCVkeHUh?=
MFH-ino MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW2[INKSzVyPUG5Mlc1PTRizszN NW\SVppnW0GQR1XS
GB-1 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHTTWM2OD1{MD6zOVM2KM7:TR?= NVrIeIZJW0GQR1XS
NCI-H1693 NFz6SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK1TWM2OD1{MD62OVA2KM7:TR?= NV2wPIY5W0GQR1XS
SW1116 NX7WVVVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1dWlEPTB;MkCuPVM3OiEQvF2= Mn\lV2FPT0WU
H-EMC-SS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofTTWM2OD1{Mj6wOFUh|ryP NUO4dHoyW0GQR1XS
D-502MG M4XsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ{LkiyOlEh|ryP Mk\JV2FPT0WU
IA-LM M{jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfze|RKSzVyPUKzMlI1QTNizszN NHXnTYtUSU6JRWK=
SW1463 M3n3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHLTWM2OD1{Mz63PUDPxE1? NYj6VZlRW0GQR1XS
JAR NEjZUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z5dGlEPTB;MkSuN|I6OyEQvF2= NFLVfIlUSU6JRWK=
HT NHvVU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ2LkS3OVMh|ryP NEDuTXlUSU6JRWK=
LCLC-103H M{PaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOzN29KSzVyPUK0Mlg1PDlizszN MXnTRW5ITVJ?
SNU-449 NF;ZUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ2Lki3OFEh|ryP MY\TRW5ITVJ?
KE-37 NXj4d3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPVTWM2OD1{NT6wPVI5KM7:TR?= MWjTRW5ITVJ?
NCI-H1623 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rTcWlEPTB;MkeuNVMxOyEQvF2= Mnz0V2FPT0WU
MOLT-13 NYXMWW9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTwTWM2OD1{Nz6zOVE3KM7:TR?= NV3xfVk6W0GQR1XS
COLO-741 NWW4SmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1SmlEPTB;M{GuN|M{OyEQvF2= MlLHV2FPT0WU
NB6 NVTqWW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN{LkK4O|Yh|ryP NGG2W3JUSU6JRWK=
MOLT-16 NW\ERYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN|LkCwOVUh|ryP MXrTRW5ITVJ?
IST-MES1 M1i1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jrbGlEPTB;M{SuNFU1OSEQvF2= MXzTRW5ITVJ?
A4-Fuk NIHpS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXhUlZKSzVyPUO1MlA3PiEQvF2= M{HsVHNCVkeHUh?=
CAL-85-1 NGXUTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLXTWM2OD1|NT6yPFE4KM7:TR?= NUG1SVEyW0GQR1XS
CCRF-CEM NXXwV2pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D4SmlEPTB;M{euNVU{PiEQvF2= NVS0bXRxW0GQR1XS
HAL-01 NGHLN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrSdGRCUUN3ME2zPE41QDh7IN88US=> M4r3UHNCVkeHUh?=
HEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rpO2lEPTB;NEOuN|QxQSEQvF2= MoDXV2FPT0WU
EW-1 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\BTWM2OD12Mz60O|Y5KM7:TR?= NYjJRYhZW0GQR1XS
MDA-MB-231 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi2R5hjUUN3ME20OU4yOTl7IN88US=> MVvTRW5ITVJ?
ABC-1 M4X3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTmS5dKSzVyPUS2Mlg2OzhizszN MnzJV2FPT0WU
NCI-H446 M3z2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fJT2lEPTB;NEiuOVA2QCEQvF2= MmjUV2FPT0WU
MHH-PREB-1 M1naOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP1V3NKSzVyPUS5MlYxODdizszN NXvxO4hxW0GQR1XS
DOHH-2 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvoUnlKSzVyPUS5MlY3PTZizszN MXvTRW5ITVJ?
GCT MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3DTWM2OD12OT62PVc3KM7:TR?= NGq2TplUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID